

Shigeki Kusamura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3887697/publications.pdf>

Version: 2024-02-01

142
papers

7,661
citations

32410

55
h-index

66518

82
g-index

147
all docs

147
docs citations

147
times ranked

4193
citing authors

#	ARTICLE	IF	CITATIONS
1	Systemic metastases from low-grade and high-grade pseudomyxoma peritonei: Treatments and outcomes. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1590-1597.	0.5	6
2	miR-550a-3p is a prognostic biomarker and exerts tumor-suppressive functions by targeting HSP90AA1 in diffuse malignant peritoneal mesothelioma. <i>Cancer Gene Therapy</i> , 2022, 29, 1394-1404.	2.2	3
3	HIPEC in Peritoneal Metastasis of Gastric Origin: A Systematic Review of Regimens and Techniques. <i>Journal of Clinical Medicine</i> , 2022, 11, 1456.	1.0	11
4	Phase II randomized study on tissue distribution and pharmacokinetics of cisplatin according to different levels of intra-abdominal pressure (IAP) during HIPEC (NCT02949791). <i>European Journal of Surgical Oncology</i> , 2021, 47, 82-88.	0.5	16
5	Prognostic Impact of Primary Side and RAS/RAF Mutations in a Surgical Series of Colorectal Cancer with Peritoneal Metastases. <i>Annals of Surgical Oncology</i> , 2021, 28, 3332-3342.	0.7	19
6	Comparative study of mucinous and non-mucinous appendiceal neoplasms with peritoneal dissemination treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). <i>European Journal of Surgical Oncology</i> , 2021, 47, 1132-1139.	0.5	12
7	Impact of Previous Gynecologic Surgical Procedures on Outcomes of Non-Gynecologic Peritoneal Malignancies Mimicking Ovarian Cancer: Less Is More?. <i>Annals of Surgical Oncology</i> , 2021, 28, 2899-2908.	0.7	5
8	The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery. <i>JAMA Surgery</i> , 2021, 156, e206363.	2.2	74
9	Prognostic impact of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer patients: A meta-analysis of randomized controlled trials. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2757-2767.	0.5	36
10	HIPEC Methodology and Regimens: The Need for an Expert Consensus. <i>Annals of Surgical Oncology</i> , 2021, 28, 9098-9113.	0.7	22
11	Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS). <i>Annals of Surgical Oncology</i> , 2020, 27, 98-106.	0.7	26
12	Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPeritoneal chemotherapy (HIPEC): Enhanced Recovery After Surgery (ERAS®) Society Recommendations – Part II: Postoperative management and special considerations. <i>European Journal of Surgical Oncology</i> , 2020, 46, 2311-2323.	0.5	79
13	Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPeritoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS®) Society Recommendations – Part I: Preoperative and intraoperative management. <i>European Journal of Surgical Oncology</i> , 2020, 46, 2292-2310.	0.5	98
14	Hemodynamic and respiratory implications of high intra-abdominal pressure during HIPEC. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1896-1901.	0.5	7
15	Peritoneal Mesothelioma: Disease Biology and Patterns of Peritoneal Dissemination. , 2020, , 117-129.		2
16	Iterative cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A multi-institutional experience. <i>Journal of Surgical Oncology</i> , 2019, 119, 336-346.	0.8	31
17	Clinico-pathological outcomes after total parietal peritonectomy, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in advanced serous papillary peritoneal carcinoma submitted to neoadjuvant systemic chemotherapy- largest single institute experience. <i>European Journal of Surgical Oncology</i> , 2019, 45, 2103-2108.	0.5	10
18	Peritoneal Mesothelioma: Diagnosis and Management. , 2019, , 301-322.		0

#	ARTICLE	IF	CITATIONS
19	Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei. <i>Clinical Colorectal Cancer</i> , 2019, 18, e179-e190.	1.0	12
20	Comments on: Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e111.	1.0	1
21	Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5817.	1.8	11
22	Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma. <i>EBioMedicine</i> , 2019, 39, 215-225.	2.7	41
23	Well differentiated papillary peritoneal mesothelioma treated by cytoreduction and hyperthermic intraperitoneal chemotherapy-the experience of the PSOGI registry. <i>European Journal of Surgical Oncology</i> , 2019, 45, 371-375.	0.5	13
24	Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases From a Small Bowel Adenocarcinoma: Multi-Institutional Experience. <i>Annals of Surgical Oncology</i> , 2018, 25, 1184-1192.	0.7	30
25	Clinical Surveillance After Macroscopically Complete Surgery for Low-Grade Appendiceal Mucinous Neoplasms (LAMN) with or Without Limited Peritoneal Spread: Long-Term Results in a Prospective Series. <i>Annals of Surgical Oncology</i> , 2018, 25, 878-884.	0.7	55
26	Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry. <i>Annals of Surgical Oncology</i> , 2018, 25, 667-673.	0.7	25
27	Multicystic mesothelioma: Operative and long-term outcomes with cytoreductive surgery and hyperthermic intra peritoneal chemotherapy. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1100-1104.	0.5	24
28	Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study. <i>European Journal of Surgical Oncology</i> , 2018, 44, 792-798.	0.5	21
29	Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2018, 25, 404-413.	0.7	61
30	Learning Curve, Training Program, and Monitorization of Surgical Performance of Peritoneal Surface Malignancies Centers. <i>Surgical Oncology Clinics of North America</i> , 2018, 27, 507-517.	0.6	27
31	Dose-Dependent Effect of Red Blood Cells Transfusion on Perioperative and Long-Term Outcomes in Peritoneal Surface Malignancies Treated with Cytoreduction and HIPEC. <i>Annals of Surgical Oncology</i> , 2018, 25, 3264-3270.	0.7	20
32	Should a History of Extraperitoneal Disease Be a Contraindication to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer Peritoneal Metastases?. <i>Diseases of the Colon and Rectum</i> , 2018, 61, 1026-1034.	0.7	25
33	Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at the Time of Primary Curative Surgery in Patients with Colorectal Cancer at High Risk for Metachronous Peritoneal Metastases. <i>Annals of Surgical Oncology</i> , 2017, 24, 167-175.	0.7	41
34	Cytoreductive Surgery and HIPEC in the First-Line and Interval Time Points of Advanced Epithelial Ovarian Cancer. <i>Indian Journal of Gynecologic Oncology</i> , 2017, 15, 11-20.	0.1	6
35	Colorectal Cancer Peritoneal Metastases. <i>Annals of Surgery</i> , 2016, 263, e5.	2.1	3
36	Pseudomyxoma Peritonei of Extra-Appendiceal Origin: A Comparative Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 4222-4230.	0.7	30

#	ARTICLE	IF	CITATIONS
37	The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). <i>Annals of Surgical Oncology</i> , 2016, 23, 1468-1473.	0.7	59
38	GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study. <i>Journal of Translational Medicine</i> , 2016, 14, 125.	1.8	36
39	Comment on the review entitled "A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer" by Chiva LM and Gonzalez-Martin A.. <i>Gynecologic Oncology Reports</i> , 2016, 15, 7-8.	0.3	3
40	Progress in treatments for colorectal cancer peritoneal metastases during the years 2010-2015. A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 209-222.	2.0	92
41	Goal-Directed Therapy for Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy: the Right Approach in the Right Place. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 1196-1197.	0.9	3
42	The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). <i>European Journal of Surgical Oncology</i> , 2015, 41, 1097-1105.	0.5	22
43	Epidural analgesia for cytoreductive surgery with peritonectomy and heated intraperitoneal chemotherapy. <i>International Journal of Surgery</i> , 2015, 16, 99-106.	1.1	22
44	The role of hyperthermic intraperitoneal chemotherapy (HIPEC) and isolated perfusion (ILP) interventions in sarcoma. <i>Journal of Surgical Oncology</i> , 2015, 111, 570-579.	0.8	11
45	In Reply. <i>Oncologist</i> , 2015, 20, e5-e5.	1.9	1
46	Peritoneal Mesothelioma. <i>Updates in Surgery Series</i> , 2015, , 243-254.	0.0	0
47	Immunohistochemical Evaluation of Minichromosome Maintenance Protein 7 (MCM7), Topoisomerase III α , and Ki-67 in Diffuse Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray. <i>Annals of Surgical Oncology</i> , 2015, 22, 4344-4351.	0.7	21
48	FOLFOX-4 Chemotherapy for Patients With Unresectable or Relapsed Peritoneal Pseudomyxoma. <i>Oncologist</i> , 2014, 19, 845-850.	1.9	48
49	Prevention and early treatment of peritoneal metastases from colorectal cancer: Second-look laparotomy or prophylactic HIPEC?. <i>Journal of Surgical Oncology</i> , 2014, 109, 225-226.	0.8	8
50	Postoperative Complications After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Affect Long-term Outcome of Patients With Peritoneal Metastases From Colorectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2014, 57, 858-868.	0.7	106
51	Multicentre study of the learning curve and surgical performance of cytoreductive surgery with intraperitoneal chemotherapy for pseudomyxoma peritonei. <i>British Journal of Surgery</i> , 2014, 101, 1758-1765.	0.1	68
52	The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. <i>Journal of Surgical Oncology</i> , 2014, 110, 779-785.	0.8	134
53	The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis. <i>Annals of Surgical Oncology</i> , 2014, 21, 4195-4201.	0.7	141
54	Carboplatin plus paclitaxel scheduling for advanced ovarian cancer. <i>Lancet Oncology</i> , The, 2014, 15, e249.	5.1	3

#	ARTICLE	IF	CITATIONS
55	The Role of Perioperative Systemic Chemotherapy in Diffuse Malignant Peritoneal Mesothelioma Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2013, 20, 1093-1100.	0.7	78
56	Diffuse malignant peritoneal mesothelioma: Long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). <i>European Journal of Cancer</i> , 2013, 49, 3140-3148.	1.3	110
57	Learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies: Analysis of two centres. <i>Journal of Surgical Oncology</i> , 2013, 107, 312-319.	0.8	69
58	Circulating tumor markers: Predictors of incomplete cytoreduction and powerful determinants of outcome in pseudomyxoma peritonei. <i>Journal of Surgical Oncology</i> , 2013, 108, 1-8.	0.8	30
59	Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Epithelial Ovarian Cancer. <i>Obstetrical and Gynecological Survey</i> , 2013, 68, 359-360.	0.2	0
60	Pilot study of adjuvant hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer at high risk for the development of peritoneal metastases. <i>Tumori</i> , 2013, 99, 589-595.	0.6	11
61	Pilot study of adjuvant hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer at high risk for the development of peritoneal metastases. <i>Tumori</i> , 2013, 99, 589-95.	0.6	9
62	Importance of gender in diffuse malignant peritoneal mesothelioma. <i>Annals of Oncology</i> , 2012, 23, 1494-1498.	0.6	47
63	Multidimensional Analysis of the Learning Curve for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Surface Malignancies. <i>Annals of Surgery</i> , 2012, 255, 348-356.	2.1	116
64	Identification of a Subgroup of Patients at Highest Risk for Complications After Surgical Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgery</i> , 2012, 256, 334-341.	2.1	70
65	Diagnostic accuracy of sentinel node in endometrial cancer by using hysteroscopic injection of radiolabeled tracer. <i>Gynecologic Oncology</i> , 2012, 126, 419-423.	0.6	68
66	The Importance of the Learning Curve and Surveillance of Surgical Performance in Peritoneal Surface Malignancy Programs. <i>Surgical Oncology Clinics of North America</i> , 2012, 21, 559-576.	0.6	30
67	Systematic Para-aortic and Pelvic Lymphadenectomy in Early Stage Epithelial Ovarian Cancer: A Prospective Study. <i>Annals of Surgical Oncology</i> , 2012, 19, 3849-3855.	0.7	61
68	Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2012, 119, 800-809.	1.1	68
69	Cytoreductive Surgery with Selective Versus Complete Parietal Peritonectomy Followed by Hyperthermic Intraperitoneal Chemotherapy in Patients with Diffuse Malignant Peritoneal Mesothelioma: A Controlled Study. <i>Annals of Surgical Oncology</i> , 2012, 19, 1416-1424.	0.7	85
70	Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer. <i>European Journal of Surgical Oncology</i> , 2011, 37, 4-9.	0.5	74
71	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: Multi-institutional phase-II trial. <i>Gynecologic Oncology</i> , 2011, 122, 215-220.	0.6	131
72	Sentinel lymph node and prognostic factors in gastric cancer. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2011, 25, 3715-3716.	1.3	0

#	ARTICLE	IF	CITATIONS
73	Diffuse malignant peritoneal mesothelioma: Systematic review of clinical management and biological research. <i>Journal of Surgical Oncology</i> , 2011, 103, 822-831.	0.8	62
74	Lymph Node Metastases in Diffuse Malignant Peritoneal Mesothelioma. <i>Annals of Surgical Oncology</i> , 2010, 17, 45-53.	0.7	72
75	In Reply: Five Reasons Why Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Must Be Regarded as the New Standard of Care for Diffuse Malignant Peritoneal Mesothelioma. <i>Annals of Surgical Oncology</i> , 2010, 17, 1713-1714.	0.7	2
76	Peritoneal Sarcomatosis: Is There a Subset of Patients Who May Benefit from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy?. <i>Annals of Surgical Oncology</i> , 2010, 17, 3220-3228.	0.7	83
77	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in a Patient with Peritoneal Mesothelioma and HIV Infection. <i>Tumori</i> , 2010, 96, 340-344.	0.6	3
78	Pathophysiology and biology of peritoneal carcinomatosis. <i>World Journal of Gastrointestinal Oncology</i> , 2010, 2, 12.	0.8	74
79	Cost analysis of the combined procedure of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). <i>European Journal of Surgical Oncology</i> , 2010, 36, 463-469.	0.5	41
80	Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). <i>European Journal of Surgical Oncology</i> , 2010, 36, 1047-1053.	0.5	37
81	Early and long-term postoperative management following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>World Journal of Gastrointestinal Oncology</i> , 2010, 2, 36.	0.8	45
82	Experience with peritoneal mesothelioma at the Milan National Cancer Institute. <i>World Journal of Gastrointestinal Oncology</i> , 2010, 2, 76.	0.8	22
83	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience. <i>Journal of Clinical Oncology</i> , 2009, 27, 6237-6242.	0.8	598
84	Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies. <i>Journal of Surgical Oncology</i> , 2009, 100, 321-328.	0.8	91
85	Diffuse Malignant Peritoneal Mesothelioma: Failure Analysis Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). <i>Annals of Surgical Oncology</i> , 2009, 16, 463-472.	0.7	46
86	Circulating CA125 and diffuse malignant peritoneal mesothelioma. <i>European Journal of Surgical Oncology</i> , 2009, 35, 1198-1199.	0.5	14
87	Pseudomyxoma Peritonei. <i>Annals of Surgery</i> , 2009, 249, 243-249.	2.1	90
88	Surgical Treatment of Peritoneal Carcinomatosis. , 2009, , 229-236.		0
89	Quality of Life and Sexual, Bladder, and Intestinal Dysfunctions After Class III Nerve-Sparing and Class II Radical Hysterectomies. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 953-957.	1.2	52
90	Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy. <i>Journal of Surgical Oncology</i> , 2008, 98, 247-252.	0.8	98

#	ARTICLE	IF	CITATIONS
91	Locoregional treatment of peritoneal carcinomatosis from gastric cancer. <i>Journal of Surgical Oncology</i> , 2008, 98, 273-276.	0.8	77
92	Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. <i>Journal of Surgical Oncology</i> , 2008, 98, 263-267.	0.8	180
93	Consensus statement on the loco regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). <i>Journal of Surgical Oncology</i> , 2008, 98, 277-282.	0.8	193
94	Consensus statement on peritoneal mesothelioma. <i>Journal of Surgical Oncology</i> , 2008, 98, 268-272.	0.8	92
95	The Fifth International Workshop on Peritoneal Surface Malignancy (Milan, Italy, December 4-6, 2006): methodology of disease-specific consensus. <i>Journal of Surgical Oncology</i> , 2008, 98, 258-262.	0.8	29
96	Morbidity, toxicity, and mortality classification systems in the local regional treatment of peritoneal surface malignancy. <i>Journal of Surgical Oncology</i> , 2008, 98, 253-257.	0.8	84
97	Technical aspects of cytoreductive surgery. <i>Journal of Surgical Oncology</i> , 2008, 98, 232-236.	0.8	20
98	The Delphi approach to Attain consensus in methodology of local regional therapy for peritoneal surface malignancy. <i>Journal of Surgical Oncology</i> , 2008, 98, 217-219.	0.8	17
99	The eligibility for local regional treatment of peritoneal surface malignancy. <i>Journal of Surgical Oncology</i> , 2008, 98, 220-223.	0.8	37
100	Hyperthermic intraperitoneal chemotherapy: Nomenclature and modalities of perfusion. <i>Journal of Surgical Oncology</i> , 2008, 98, 242-246.	0.8	122
101	The consensus statement on the locoregional treatment of abdominal sarcomatosis. <i>Journal of Surgical Oncology</i> , 2008, 98, 291-294.	0.8	36
102	The intraoperative staging systems in the management of peritoneal surface malignancy. <i>Journal of Surgical Oncology</i> , 2008, 98, 228-231.	0.8	104
103	Preoperative investigations in the management of peritoneal surface malignancy with cytoreductive surgery and perioperative intraperitoneal chemotherapy: Expert consensus statement. <i>Journal of Surgical Oncology</i> , 2008, 98, 224-227.	0.8	78
104	Postoperative residual disease evaluation in the locoregional treatment of peritoneal surface malignancy. <i>Journal of Surgical Oncology</i> , 2008, 98, 237-241.	0.8	56
105	Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. <i>Journal of Surgical Oncology</i> , 2008, 98, 283-290.	0.8	56
106	Pseudomyxoma Peritonei: Clinical Pathological and Biological Prognostic Factors in Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). <i>Annals of Surgical Oncology</i> , 2008, 15, 526-534.	0.7	167
107	Hysteroscopy in endometrial cancer: new methods to evaluate transtubal leakage of saline distension medium. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 198, 214.e1-214.e4.	0.7	18
108	Multiple Mechanisms of Telomere Maintenance Exist and Differentially Affect Clinical Outcome in Diffuse Malignant Peritoneal Mesothelioma. <i>Clinical Cancer Research</i> , 2008, 14, 4134-4140.	3.2	61

#	ARTICLE	IF	CITATIONS
109	Nerve-sparing radical hysterectomy in cervical cancer: Evolution of concepts. <i>Gynecologic Oncology</i> , 2007, 107, S119-S121.	0.6	31
110	Circulating CA125 in Patients with Peritoneal Mesothelioma Treated with Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion. <i>Annals of Surgical Oncology</i> , 2007, 14, 500-508.	0.7	72
111	Prognostic Value of Circulating Tumor Markers in Patients with Pseudomyxoma Peritonei Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2007, 14, 2300-2308.	0.7	87
112	Impact of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Systemic Toxicity. <i>Annals of Surgical Oncology</i> , 2007, 14, 2550-2558.	0.7	69
113	Multicystic and Well-differentiated Papillary Peritoneal Mesothelioma Treated by Surgical Cytoreduction and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC). <i>Annals of Surgical Oncology</i> , 2007, 14, 2790-2797.	0.7	45
114	Incidence of Postoperative Pancreatic Fistula and Hyperamylasemia after Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2007, 14, 3443-3452.	0.7	23
115	Morbidity and Quality of Life following Cytoreduction and HIPEC. , 2007, 134, 403-418.		10
116	Advances in Clinical Research and Management of Diffuse Peritoneal Mesothelioma. , 2007, 169, 137-155.		3
117	Survivin is Highly Expressed and Promotes Cell Survival in Malignant Peritoneal Mesothelioma. <i>Analytical Cellular Pathology</i> , 2007, 29, 453-466.	0.7	35
118	Surgical Treatment in FIGO Stage I Cervical Cancer: Evolution of Concepts. <i>Current Women's Health Reviews</i> , 2007, 3, 129-137.	0.1	0
119	Regional Therapy in Ovarian Cancer. , 2007, , 329-341.		0
120	Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan. <i>European Journal of Surgical Oncology</i> , 2006, 32, 671-675.	0.5	105
121	CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases. <i>Histopathology</i> , 2006, 49, 381-387.	1.6	46
122	Prognostic Analysis of Clinicopathologic Factors in 49 Patients With Diffuse Malignant Peritoneal Mesothelioma Treated With Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion. <i>Annals of Surgical Oncology</i> , 2006, 13, 229-237.	0.7	144
123	Type II versus Type III Nerve-sparing Radical hysterectomy: Comparison of lower urinary tract dysfunctions. <i>Gynecologic Oncology</i> , 2006, 102, 256-262.	0.6	81
124	Clinical and pathological prognostic factors in squamous cell carcinoma of the vulva. <i>Gynecologic Oncology</i> , 2006, 102, 333-337.	0.6	94
125	Photodynamic therapy using a methyl ester of 5-aminolevulinic acid in recurrent Paget's disease of the vulva: A pilot study. <i>Gynecologic Oncology</i> , 2006, 103, 581-586.	0.6	80
126	Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion. <i>Cancer</i> , 2006, 106, 1144-1153.	2.0	234

#	ARTICLE	IF	CITATIONS
127	Bowel Complications in 203 Cases of Peritoneal Surface Malignancies Treated With Peritonectomy and Closed-Technique Intraperitoneal Hyperthermic Perfusion. <i>Annals of Surgical Oncology</i> , 2005, 12, 910-918.	0.7	69
128	Lymphatic mapping for endometrial cancer: Is hysteroscopic injection a safe technique for sentinel lymph node biopsy?. <i>American Journal of Obstetrics and Gynecology</i> , 2005, 193, 1880-1881.	0.7	6
129	Prognostic factors in microinvasive cervical squamous cell cancer: long-term results. <i>International Journal of Gynecological Cancer</i> , 2005, 15, 88-93.	1.2	21
130	Diffuse malignant mesothelioma of the peritoneum. <i>Cancer</i> , 2005, 104, 2181-2188.	2.0	82
131	Nerve-sparing radical hysterectomy: a surgical technique for preserving the autonomic hypogastric nerve. <i>Gynecologic Oncology</i> , 2004, 93, 307-314.	0.6	119
132	Hysteroscopic injection of tracers in sentinel node detection of endometrial cancer: a feasibility study. <i>American Journal of Obstetrics and Gynecology</i> , 2004, 191, 435-439.	0.7	77
133	Peritonectomy and Intraperitoneal Hyperthermic Perfusion (IPHP): A Strategy That Has Confirmed its Efficacy in Patients with Pseudomyxoma Peritonei. <i>Annals of Surgical Oncology</i> , 2004, 11, 393-398.	0.7	157
134	Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis. <i>Cancer</i> , 2004, 100, 1943-1950.	2.0	103
135	Gemcitabine Combined with Oxaliplatin (GEMOX) as Second-Line Chemotherapy in Patients with Advanced Ovarian Cancer Refractory or Resistant to Platinum and Taxane. <i>Oncology</i> , 2004, 67, 376-381.	0.9	28
136	Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. <i>Journal of Surgical Oncology</i> , 2003, 83, 147-153.	0.8	77
137	Expression of p53, c-erbB-2, Ki-67, and CD34 in granulosa cell tumor of the ovary. <i>International Journal of Gynecological Cancer</i> , 2003, 13, 450-457.	1.2	16
138	Management of peritoneal surface component of ovarian cancer. <i>Surgical Oncology Clinics of North America</i> , 2003, 12, 561-583.	0.6	27
139	Feasibility of Peritonectomy Associated with Intraperitoneal Hyperthermic Perfusion in Patients with Pseudomyxoma Peritonei. <i>Tumori</i> , 2002, 88, 370-375.	0.6	17
140	Feasibility of peritonectomy associated with intraperitoneal hyperthermic perfusion in patients with Pseudomyxoma peritonei. <i>Tumori</i> , 2002, 88, 370-5.	0.6	12
141	Cytoreductive Surgery Followed by Intraperitoneal Hyperthermic Perfusion in the Treatment of Recurrent Epithelial Ovarian Cancer: A Phase II Clinical Study. <i>Tumori</i> , 2001, 87, 120-126.	0.6	77
142	Ovarian Germ Cell Cancer: Clinicopathologic Analysis and Outcome of 31 Cases. <i>Tumori</i> , 2000, 86, 450-454.	0.6	3